

EGFR T790M RealFast™ Assay

A reliable tool to personalize therapy of lung cancer patients with acquired TKI-resistance mutation T790M in the *EGFR* gene

Liquid profiling of NSCLC patients

The EGFR T790M RealFast™ Assay detects the most common resistance mutation in plasma-derived, circulating cell-free DNA (cfDNA) from non-small-cell lung cancer (NSCLC) patients. As the epidermal growth factor receptor (EGFR) plays a crucial role in cell proliferation and growth, NSCLC patients with activating *EGFR* mutations in exons 18 and 21 may benefit from EGFR tyrosine kinase inhibitor (TKI) therapy. However, acquired resistance to these TKIs is frequent, with the T790M (c.2369C>T) mutation accounting

for 50%-60% of the underlying mechanisms. Treatment with Osimertinib (Tagrisso®) has been established as an alternative therapy in patients who are positive for *EGFR* T790M.


The ViennaLab **Plasma cfDNA Extraction Kit** is a column-based sample preparation kit allowing the extraction of high-purity cell-free DNA from up to 4 mL plasma. It has been developed and validated for use with the EGFR T790M RealFast™ Assay.

ViennaLab EGFR T790M RealFast™ Assay

| |
|--|
| • For use with cell-free DNA samples obtained from plasma |
| • Highly sensitive (Limit of Detection: 8 mutant copies in 2.5 ng cfDNA) |
| • Compatible with a wide range of real-time PCR instruments |
| • Positive control included |
| • RealFast™ Assay for in vitro diagnostic use |



REF: • EGFR T790M RealFast™ Assay: 8-110/8-113 (100/32 reactions) • Plasma cfDNA Extraction Kit [RUO]: 2-040 (50 extractions)

 Manufacturer:
ViennaLab Diagnostics GmbH
 Gaudenzdorfer Guertel 43-45
 A-1120 Vienna, Austria
 www.viennalab.com

t: (+43-1) 8120156-0
 e: info@viennalab.com

Distributor: